Navigation Links
Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
Date:10/10/2011

thod, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions tar
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
3. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
4. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
5. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
6. Inovio Pharmaceuticals to Present at Investor Conferences
7. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
8. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
9. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
10. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
11. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. , Titled "Evidence-Conformant ... developed at UH to enhance care for adult cancer ... for high health care utilization. , "We ...
(Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2
... Department of Defense (DOD) Breast Cancer Research Program (BCRP) ... Programs has awarded Silvia Formenti, MD, the Sandra and ... Radiation Oncology a $4.5 million Multi-Team Award to conduct ... offers tremendous promise for new therapeutic options for patients ...
... News) -- Certain gene mutations influence how likely people ... counter to experience, say researchers at Brown University. ... without gene mutations that affect the activity of the ... the prefrontal cortex and the striatum. The prefrontal ...
... TUESDAY, April 19 (HealthDay News) -- Nearly one-third of ... experience depression after the injury, a new study finds. ... existing research on blunt force trauma head injuries suffered ... "Any patient who has a traumatic brain injury ...
... release is available in German . ... consequences: Around first grade, the children start experiencing vision ... complete blindness. This is the first indication of a ... experience hallucinations, epileptic seizures, dementia and, finally, failure of ...
... glioma from chemoradiation may result in improved patient survival, ... Kimmel Cancer Center at Jefferson suggests. These ... the British Journal of Cancer . The ... such as fatigue and loss of short-term memory, that ...
... implants appear to be associated with a rare form of lymphoma, ... is caused by implants or to suggest an underlying mechanism for ... from the RAND Corporation. The study, published online by ... the disease takes a slow course and can be controlled by ...
Cached Medicine News:Health News:NYU Langone Medical Center awarded $4.5 million for breast cancer research 2Health News:Depression Common After Brain Injury 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study confirms link between breast implants and rare form of cancer 2Health News:Study confirms link between breast implants and rare form of cancer 3
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: